CD274 and melanoma: Sustained IFN type I exposure was shown to lead to the resistance of B16 melanoma tumors to ICI therapy through a mechanism involving the overexpression of several immune checkpoints (CD86, TNFRSF14, PDL1, and LGALS9) [159,160].